We conducted a large-scale surveillance study as a post-marketing commitment to investigate the safety and effectiveness of alectinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) in Japan. Patients receiving 300 mg twicedaily alectinib (September 2014 to June 2015) were monitored until termination of alectinib or completion of 18 months of treatment at 519 Japanese study sites.
We conducted a large-scale surveillance study as a post-marketing commitment to investigate the safety and effectiveness of alectinib in patients with ALK-positive non-small-cell lung cancer (NSCLC) in Japan. Patients receiving 300 mg twicedaily alectinib (September 2014 to June 2015) were monitored until termination of alectinib or completion of 18 months of treatment at 519 Japanese study sites.
The primary endpoint was the incidence of adverse drug reactions (ADR), which are important identified risks for alectinib in Japanese patients. Overall survival (OS), a key secondary endpoint, was assessed according to information on outcome. Overall, 1251 patients were enrolled. The median patient age was 62.0 years; 12.9% of patients were aged ≥75 years. At baseline, 63.0% of patients had received crizotinib and 40.6% had brain metastases. Altogether, 1512 ADR occurred in 654 patients (53.6%), with 164 grade ≥3 ADR in 123 patients (10.1%). Commonly occurring ADR were hepatic disorders (all grades, 19.8%; grade ≥3, 2.0%), decreased neutrophil and/or white blood cell count (all grades, 7.6%; grade ≥3, 1.1%), and interstitial lung disease (all grades, 3.8%; grade ≥3, .7%). Median OS was not estimable. The 18-month cumulative OS rate was longer in patients with ECOG performance status ≤1 (vs 2 or ≥3; 83.7% vs 44.5% or 27.2%), without prior crizotinib (vs with; 81.1% vs 73.4%), receiving first-line alectinib (vs second and third or later line; 83.0% vs 79.2% or 71.9%), without brain metastases (vs with; 79.5% vs 71.5%). These data confirm the favorable safety and effectiveness of alectinib in patients with ALK-positive NSCLC in Japan.
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| INTRODUC TI ON
Non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase fusion gene-rearrangement (ALK-positive) is a distinct subset of lung cancer occurring in approximately 5% of advanced adenocarcinoma cases.
1-3 The central nervous system (CNS) active and highly selective ALK inhibitor alectinib is approved by the US Food and Drug Administration and the European Medicines Agency, and is recommended as a preferred first-line treatment option for ALKpositive NSCLC in the NCCN guidelines.
4
Approval of alectinib in Japan was based on data from a phase I/II study of ALK inhibitor-naïve patients with ALK-positive NSCLC who received alectinib 300 mg twice daily (AF-001JP). 5, 6 Using data from the AF-001JP study, the Japanese Risk Management Plan (J-RMP) identified interstitial lung disease (ILD), liver function disorder, and decreased neutrophil and/or white blood cell (WBC) counts as important risks for Japanese patients receiving alectinib.
To investigate the safety and effectiveness of alectinib in patients with ALK-positive NSCLC in Japan, including adverse drug reactions (ADR; treatment-related adverse events [AE]) of particular concern, a large-scale surveillance study was implemented in Japan as part of a post-marketing commitment. Here, we report the study outcomes.
| PATIENTS AND ME THODS

| Study design
This multicenter surveillance study examined the safety and effectiveness of alectinib in all patients with ALK-positive NSCLC in Japan The primary study endpoint was the incidence of ADR, including ILD, hepatic disorders, and decreased neutrophil and/or WBC counts, which are important identified risks for alectinib treatment in Japanese patients. Overall survival (OS) was a key secondary endpoint and was assessed according to information on outcome.
The study was conducted in accordance with Good Post-marketing Study Practice regulations from the Japanese Ministry of Health, Labour, and Welfare, and the study protocol was approved by the relevant ethics committees at the participating sites.
| Assessments
Demographic and baseline data were collected, including age, gen- RT-PCR, reverse transcriptase-polymerase chain reaction; SD, standard deviation. a n = 1220.
| Statistical analyses
The planned sample size was 1000 patients, which was the number required to identify ADR with an incidence of .3% in at least 1 patient with a probability of ≥95%. The safety population comprised all patients who received at least 1 dose of alectinib and had avail- were enrolled, of whom 1221 patients formed the safety population and 1194 patients formed the effectiveness population ( Figure S1 ).
Baseline patient characteristics are summarized in Table 1 . There were slightly more women than men (53.8% women [n = 657], 46.1% men [n = 563]). The median patient age was 62.0 years and 12.9%
of patients (n = 158) were aged ≥75 years. ECOG PS score was ≥2 in 16.1% of patients (n = 197) and ≥3 in 7.3% of patients (n = 89). Baseline brain metastases were present in 40.6% of patients (n = 496).
The results of ALK fusion gene testing were positive by both FISH and IHC in 63.1% of patients (n = 770; Table 1 ). Overall, 63.0% of patients (n = 769) had a history of crizotinib pretreatment.
Alectinib was administered as first-line treatment in 18.3% of patients (n = 223), second line in 31.6% of patients (n = 386), third line in 22.8% of patients (n = 278), and as fourth line or later in 26.8% of patients (n = 327) ( Table 1) , reflecting the real-world setting of this study.
| Treatment duration
The median time to treatment failure was 482.0 days (range 1-775). (Table S1 ).
| Adverse drug reactions
The incidence of ADR in patient subgroups defined by baseline characteristics was comparable with the overall safety population ( common grade ≥3 events in patients with ECOG PS ≥2 (n = 197). 
| Interstitial lung disease
According to physician-assessed data, 48 ILD events were reported in 47/1221 patients (3.8%). All of these were serious, except for 1 event of pulmonary fibrosis, which was classed as non-serious. ILD medical expert, the possibility that 1 patient died as a result of an ILD could not be refuted. (Table 4) . 
| Hepatic disorders
| Survival
Of the 1194 patients in the effectiveness population, 1191 were included in the OS analysis, and 247 events occurred. Three patients were excluded from the OS analysis because of missing data (ie, information was missing on the initial dosing date of alectinib, outcome or survival). Median OS could not be estimated during the observation period. (Figure 3 ).
| D ISCUSS I ON
Data from this large-scale, real-world surveillance study confirm the acceptable safety and effectiveness profile of alectinib in patients with ALK-positive NSCLC in Japan. We observed no increased incidence of ADR compared with the pivotal AF-001JP phase I/II alectinib study 5 or the Japanese bioequivalence study. 7 The ADR were generally mild in intensity and managed effectively when alectinib was used according to the utility guidance and treatment handbook for patients. However, these results must be interpreted with caution due to the different study populations enrolled; that is, the pre-approval studies did not include patients with ECOG PS ≥2, or with crizotinib pretreatment, and included fewer patients aged ≥75 years. Furthermore, we did not see any increased incidence of F I G U R E 1 Incidence of interstitial lung disease (ILD) from start of alectinib administration to onset of ILD There was no marked difference in the incidence of ILD in the present study (3.8%) and that reported in the AF-001JP (1.7%) 5 and phase III J-ALEX (8%) 10 Japanese alectinib studies, or in the global PROFILE crizotinib studies (3.7%), 11 or the ASCEND-1/2 ceritinib studies (1%-4%). 12 However, as an independent ILD medical expert could not refute the possibility that 1 patient died as a result of an ILD, it is important to continually monitor for signs of ILD during alectinib treatment. Again, caution should be exercised in comparing these results with previous study findings due to differences in patient characteristics and study observation periods.
The cumulative OS rate achieved in our study did not differ considerably from that reported in the AF-001JP study, 5 in which the 2-year and 3-year survival rates were 79% (95% CI, 63-89) and 78%
(95% CI, 63-88), respectively. The 18-month cumulative survival rate seen in patients with baseline metastases was also comparable with that reported in study AF-001JP. 5 However, results cannot be compared directly due to differences in patient baseline characteristics and the duration of the observation period.
A strength of the current study was its very large size, but it was limited by the lack of a comparator group or control arm, and the absence of a strict observation period or patient selection criteria.
However, this could also be considered a strength as it is more re- 
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